Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.

[1]  T. Choueiri,et al.  First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC , 2014, British Journal of Cancer.

[2]  C. Porta,et al.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[3]  T. Choueiri,et al.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. , 2014, European urology.

[4]  A. Palazzo,et al.  Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. , 2014, Cancer treatment reviews.

[5]  T. Choueiri,et al.  The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). , 2014 .

[6]  J. Himmelfarb,et al.  Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib , 2014 .

[7]  C. Sternberg,et al.  Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. , 2013, European journal of cancer.

[8]  B. Escudier,et al.  Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. , 2013, European journal of cancer.

[9]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[10]  M. Menon,et al.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[12]  P. Tamboli,et al.  Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma , 2010, Cancer.

[13]  R. Figlin,et al.  Targeted therapies for renal cell carcinoma: understanding their impact on survival , 2010, Targeted Oncology.

[14]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.